A Narrative Review of Secukinumab in Spondyloarthritis and Psoriatic Arthritis: Treating the Whole Patient
Open Access
- 19 March 2026
- journal article
- review article
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 13 (3) , 467-490
Abstract
Spondyloarthritis (SpA), including axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), comprises a diverse but interrelated family of inflammatory diseases characterized by inflammation of the joints and spine. Signs and symptoms of SpA vary widely, as patients experience a diverse spectrum of musculoskeletal and extra-musculoskeletal disease manifestations. Interleukin (IL)-17 is an inflammatory cytokine common to the pathogenesis of SpA disease development and progression. The IL-17A inhibitor secukinumab has been well established in clinical trials and real-world practice as an effective therapeutic tool to efficiently manage SpA indications axSpA and PsA in adults, as well as juvenile PsA (jPsA) and enthesitis-related arthritis (ERA), which are two subtypes of juvenile idiopathic arthritis. This review highlights the comprehensive response to IL-17 inhibition with secukinumab across SpA indications of PsA, axSpA, and ERA/jPsA and within each indication according to established disease domains. We provide context through expert commentary on the effect of inhibiting IL-17 with secukinumab on the full spectrum of SpA disease manifestations, as well as areas in need of further investigation.Keywords
Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 97 references indexed in Scilit:
- Axial SpondyloarthritisJAMA, 2025
- Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Association With Disease Severity Assessment in a Large US RegistryArthritis Care & Research, 2024
- The International Map of Axial Spondyloarthritis Survey: A US Patient Perspective on Diagnosis and Burden of DiseaseACR Open Rheumatology, 2023
- Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 StudiesACR Open Rheumatology, 2020
- 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisArthritis Care & Research, 2019
- Development and Retrospective Validation of the Juvenile Spondyloarthritis Disease Activity IndexArthritis Care & Research, 2014
- Classification criteria for psoriatic arthritis: Development of new criteria from a large international studyArthritis & Rheumatism, 2006
- Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitisArthritis & Rheumatism, 2001
- Preliminary definition of improvement in juvenile arthritisArthritis & Rheumatism, 1997
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995